GILEAD’S mega blockbuster
Sovaldi is the first of a range of
novel therapies to enter the hep C
market and is projected to hit close
to US$10b during its first year.
With no hepatitis C vaccine
anticipated and incidence rates on
the rise, the market was becoming
more attractive to big pharma, said
industry analysts Frost & Sullivan.
Solvadi’s 12 week oral course cost
$84,000, said the analysts, but had
shown close to 100% cure rates,
which meant that all newcomers
would need to be at least equal in
efficacy but be able to demonstrate
results more cost-effectively and
preferably with a shorter duration
of therapy.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.